Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 276Carcinoma, Non-Small-Cell Lung 243Neoplasms 227Prostatic Neoplasms 185Colorectal Neoplasms 175Multiple Myeloma 135Lung Neoplasms 132Ovarian Neoplasms 118Neoplasm Metastasis 118Leukemia, Myeloid, Acute 107Pancreatic Neoplasms 102Melanoma 90Squamous Cell Carcinoma of Head and Neck 87Recurrence 78Endometrial Neoplasms 75Carcinoma, Renal Cell 71Lymphoma, Non-Hodgkin 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Lymphoma 66Stomach Neoplasms 64Glioblastoma 63Carcinoma, Hepatocellular 63Brain Neoplasms 62Glioma 60Sarcoma 57Head and Neck Neoplasms 57Uterine Cervical Neoplasms 56Triple Negative Breast Neoplasms 55Leukemia, Lymphocytic, Chronic, B-Cell 54Urinary Bladder Neoplasms 50

Interventions

sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × MSI-H × 30 days × Clear all
NCT05890742 2026-05-28

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Active not recruiting
453 enrolled
Other solid neoplasm

MSI-H

Data powered by HemOnc (CC BY 4.0) Colophon âš¡